These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 4111174)

  • 1. [Myelofibrosis--a reclassified blood disease].
    Cronberg S
    Lakartidningen; 1972 Jan; 68(5):486-90. PubMed ID: 4111174
    [No Abstract]   [Full Text] [Related]  

  • 2. The spleen as a source of colony-forming cells in myelofibrosis.
    Adamson JW; Powell JS
    Prog Clin Biol Res; 1984; 154():323-34. PubMed ID: 6382301
    [No Abstract]   [Full Text] [Related]  

  • 3. [Leukocyte alkaline phosphatase and glucose-6-phosphate-dehydrogenase of the erythrocytes in differential diagnosis of chronic myeloproliferative diseases (author's transl)].
    Hennemann HH; Schief A
    Med Klin; 1974 Aug; 69(34):1359-63. PubMed ID: 4530151
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chronic myeloproliferative syndromes].
    de Ozalla CB; García Suárez J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
    [No Abstract]   [Full Text] [Related]  

  • 5. [A "myeloproliferative syndrome" of long duration (author's transl)].
    Kühböck J; Peskar BM; Vormittag W
    Med Klin; 1974 Mar; 69(10):423-6. PubMed ID: 4524608
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical-hematological variants of osteomyelosclerosis].
    Smirnov VN; Maksimova IN
    Sov Med; 1968 Jun; 31(6):100-3. PubMed ID: 5741577
    [No Abstract]   [Full Text] [Related]  

  • 7. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
    Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
    Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism.
    Hasselbalch HC
    Dan Med Bull; 1993 Mar; 40(1):39-55. PubMed ID: 8472598
    [No Abstract]   [Full Text] [Related]  

  • 11. Myeloproliferative disorder and tuberculosis.
    Herman I
    Calif Med; 1966 Oct; 105(4):287-90. PubMed ID: 5976885
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.
    Pullarkat V; Bass RD; Gong JZ; Feinstein DI; Brynes RK
    Am J Hematol; 2003 Jan; 72(1):8-12. PubMed ID: 12508261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic parameters of altered collagen turnover.
    Hahn EG; Hochweiss S; Berk PD
    Prog Clin Biol Res; 1984; 154():335-43. PubMed ID: 6382302
    [No Abstract]   [Full Text] [Related]  

  • 15. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chromosome findings in myeloproliferative diseases].
    Hellriegel KP
    Internist (Berl); 1968 Dec; 9(12):465-70. PubMed ID: 4891471
    [No Abstract]   [Full Text] [Related]  

  • 17. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Osteomyelofibrosis as a prognostic factor in myeloproliferative diseases?].
    Wehmeier A; Schneider W
    Dtsch Med Wochenschr; 1993 May; 118(21):804-5. PubMed ID: 8504717
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.